

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
March 18, 2019**

**ORDER GRANTING CONFIDENTIAL TREATMENT  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**Immunogen, Inc.**

**File No. 0-17999 - CF#37158**

---

Immunogen, Inc. submitted an application under Rule 24b-2 requesting an extension of previous grants of confidential treatment for information it excluded from the exhibits to the filings listed below.

Based on representations by Immunogen, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

<b>Exhibit</b>	<b>to Form</b>	<b>Filed on</b>	<b>Confidential Treatment Granted</b>
10.3	10-Q	February 8, 2007	through February 8, 2026
10.1	10-Q	May 9, 2007	through February 8, 2026
10.2	10-Q	May 9, 2007	through February 8, 2026
10.1	10-Q	May 7, 2009	through February 8, 2026

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Vanessa Countryman  
Acting Secretary